Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma.
作者信息
He Jian, Liu Yang
机构信息
Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
出版信息
EBioMedicine. 2016 Oct;12:4-5. doi: 10.1016/j.ebiom.2016.09.018. Epub 2016 Sep 20.
Abstract
摘要
相似文献
1
Serum TGF-β1: A Potential Biomarker for Early Detection of Hepatocellular Carcinoma.
EBioMedicine. 2016 Oct;12:4-5. doi: 10.1016/j.ebiom.2016.09.018. Epub 2016 Sep 20.
2
Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):288-95.
3
Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study.
EBioMedicine. 2016 Oct;12:68-71. doi: 10.1016/j.ebiom.2016.09.001. Epub 2016 Sep 2.
4
TGF-beta1 and C-erb-B2 neu oncoprotein in Egyptian HCV related chronic liver disease and hepatocellular carcinoma patients.
Egypt J Immunol. 2008;15(1):39-50.
5
High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Clin Cancer Res. 2015 Aug 15;21(16):3678-84. doi: 10.1158/1078-0432.CCR-14-1954. Epub 2015 May 14.
6
Hepatocellular carcinoma tumour markers: current role and expectations.
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):843-53. doi: 10.1016/j.bpg.2014.07.018. Epub 2014 Aug 22.
7
Epidermal growth factor, its receptor and transforming growth factor-β1 in the diagnosis of HCV-induced hepatocellular carcinoma.
Med Oncol. 2013;30(3):673. doi: 10.1007/s12032-013-0673-x. Epub 2013 Aug 3.
8
Circulating TGF-β1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores.
Cancer Lett. 2014 Oct 28;353(2):264-71. doi: 10.1016/j.canlet.2014.07.029. Epub 2014 Jul 31.
9
Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment.
Digestion. 1998 Jul;59 Suppl 2:72-4. doi: 10.1159/000051429.
10
Increased Serum Endoglin and Transforming Growth Factor β1 mRNA Expression and Risk of Hepatocellular Carcinoma in Cirrhotic Egyptian Patients.
Asian Pac J Cancer Prev. 2016;17(5):2429-34.
本文引用的文献
1
Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study.
EBioMedicine. 2016 Oct;12:68-71. doi: 10.1016/j.ebiom.2016.09.001. Epub 2016 Sep 2.
2
An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.
EBioMedicine. 2015 Mar 13;2(5):438-46. doi: 10.1016/j.ebiom.2015.03.010. eCollection 2015 May.
3
TGF-β signaling in onset and progression of hepatocellular carcinoma.
Dig Dis. 2012;30(5):514-23. doi: 10.1159/000341704. Epub 2012 Oct 24.
4
Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.
Cancer Lett. 2013 Nov 1;340(2):247-53. doi: 10.1016/j.canlet.2012.09.027. Epub 2012 Oct 12.
5
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
Eur J Cancer. 2012 Mar;48(5):599-641. doi: 10.1016/j.ejca.2011.12.021.
6
Evaluating prognostic accuracy of biomarkers in nested case-control studies.
Biostatistics. 2012 Jan;13(1):89-100. doi: 10.1093/biostatistics/kxr021. Epub 2011 Aug 19.
7
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.
J Gastroenterol. 2010 Dec;45(12):1272-82. doi: 10.1007/s00535-010-0278-5. Epub 2010 Jul 13.
8
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.
J Hepatol. 2005 Sep;43(3):434-41. doi: 10.1016/j.jhep.2005.03.019.
9
Screening for liver cancer: results of a randomised controlled trial in Qidong, China.
J Med Screen. 2003;10(4):204-9. doi: 10.1258/096914103771773320.
10
Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer.
J Med Screen. 1999;6(2):108-10. doi: 10.1136/jms.6.2.108.
Zotero 插件